More Episodes

3D Organoid Cell Culture – Optimising disease models for research and drug discovery

In this episode, we examine the use of 3D organoid cell culture systems as applied to cancer research and the development of novel anti-oncologic drugs. Collectively, this transition from 3D spheroid culture to organoid culture allows researchers to generate multiple organ-specific cell types, resulting in cell architectures that more closely resemble the human tissue microenvironment. […]

Listen now

Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to improve human health, biotech and pharmaceutical companies are devoting greater […]

Listen now

From Genotype to Phenotype: Leveraging functional genomics in oncology

Drug discovery is increasingly informed by genomics, which can significantly boost the chances of a novel therapy successfully navigating the lengthy journey from bench to bedside. But despite the rapid proliferation of genomic information, we still have a limited understanding of how specific genes and genetic variations drive tumour growth and therapeutic resistance. In turn, […]

Listen now

Flow Cytometry – The advanced systems overcoming drug discovery pain points

Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across a wide range of drug discovery applications. In this article, we look at novel developments in flow cytometer reagent and instrument design, and […]

Listen now

Cell Therapy – Falling short of its potential?

Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges; overcoming transplant rejection (and GvHD in the case of immune cells), producing and culturing functional cells […]

Listen now